Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Endocrinol Metab. 2005 Mar;16(2):73-8.

Antagonists of activin signaling: mechanisms and potential biological applications.

Author information

1
Prince Henry's Institute of Medical Research, 246 Clayton Road, Clayton, VIC 3168, Australia. craig.harrison@phimr.monash.edu.au

Abstract

Activins are members of the transforming growth factor-beta (TGF-beta) superfamily that control many physiological processes such as cell proliferation and differentiation, immune responses, wound repair and various endocrine activities. Activins elicit these diverse biological responses by signaling via type I and type II receptor serine kinases. Recent studies have revealed details of the roles of inhibin, betaglycan, follistatin and its related protein follistatin-related gene (FLRG), Cripto and BAMBI in antagonizing activin action, and exogenous antagonists against the activin type I (SB-431542 and SB-505124) and type II (activin-M108A) receptors have been developed. Understanding how activin signaling is controlled extracellularly is the first step in providing treatment for wound healing and for disorders such as cachexia and cancer, which result from a deregulated activin pathway.

PMID:
15734148
DOI:
10.1016/j.tem.2005.01.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center